γδ T cells: origin and fate, subsets, diseases and immunotherapy.
γδ T cells: origin and fate, subsets, diseases and immunotherapy.
复制标题
γδ T细胞:起源和命运,亚群,疾病和免疫治疗。
DOI:
10.1038/s41392-023-01653-8
复制
发表时间:
2023-11-22
影响因子:
39.3
通讯作者:
Wu, Yangzhe
中科院分区:
文献类型:
--
作者:
Hu, Yi;Hu, Qinglin;Li, Yongsheng;Lu, Ligong;Xiang, Zheng;Yin, Zhinan;Kabelitz, Dieter;Wu, Yangzhe
The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and hyperactivation, highlights the potential of immune renormalization as a promising strategy in disease treatment. In recent years, our primary focus has centered on γδ T cell-based immunotherapy, particularly pioneering the use of allogeneic Vδ2+ γδ T cells for treating late-stage solid tumors and tuberculosis patients. However, we recognize untapped potential and optimization opportunities to fully harness γδ T cell effector functions in immunotherapy. This review aims to thoroughly examine γδ T cell immunology and its role in diseases. Initially, we elucidate functional differences between γδ T cells and their αβ T cell counterparts. We also provide an overview of major milestones in γδ T cell research since their discovery in 1984. Furthermore, we delve into the intricate biological processes governing their origin, development, fate decisions, and T cell receptor (TCR) rearrangement within the thymus. By examining the mechanisms underlying the anti-tumor functions of distinct γδ T cell subtypes based on γδTCR structure or cytokine release, we emphasize the importance of accurate subtyping in understanding γδ T cell function. We also explore the microenvironment-dependent functions of γδ T cell subsets, particularly in infectious diseases, autoimmune conditions, hematological malignancies, and solid tumors. Finally, we propose future strategies for utilizing allogeneic γδ T cells in tumor immunotherapy. Through this comprehensive review, we aim to provide readers with a holistic understanding of the molecular fundamentals and translational research frontiers of γδ T cells, ultimately contributing to further advancements in harnessing the therapeutic potential of γδ T cells.
登录
查看更多内容
DOI:
10.1084/jem.20181960
发表时间:
2018-12-03
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Jameson JM
通讯作者:
Jameson JM
DOI:
10.7759/cureus.10301
发表时间:
2020-09-07
期刊:
Cureus
影响因子:
--
作者:
Hoard R;Shahin G;Andreca FD;Osswald M
通讯作者:
Osswald M
DOI:
10.1084/jem.184.6.2167
发表时间:
1996-12-01
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Harrison LC;Dempsey-Collier M;Kramer DR;Takahashi K
通讯作者:
Takahashi K
影响因子:
30.5
作者:
Alves de Lima K;Rustenhoven J;Da Mesquita S;Wall M;Salvador AF;Smirnov I;Martelossi Cebinelli G;Mamuladze T;Baker W;Papadopoulos Z;Lopes MB;Cao WS;Xie XS;Herz J;Kipnis J
通讯作者:
Kipnis J
影响因子:
5.8
作者:
Altvater, Bianca;Pscherer, Sibylle;Rossig, Claudia
通讯作者:
Rossig, Claudia